OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx (OPRX) will integrate its authenticated point of care inventory with The Trade Desk’s OpenPath in the fourth quarter of 2026.
Through this integration, advertisers using The Trade Desk’s demand-side platform will gain direct programmatic access to OptimizeRx’s proprietary network of more than 400 electronic health record and e-prescribe systems, reaching about 800,000 verified healthcare professionals. The move brings in‑workflow EHR placements into mainstream programmatic buying, giving life sciences marketers another way to include point of care inventory within broader omnichannel and HCP media strategies.
OptimizeRx (OPRX) has expanded its AI-powered Natural Language Audience Builder (NLAB) so media planners can create both claims-grade healthcare professional (HCP) and privacy-safe direct-to-consumer (DTC) audiences in a single, plain-language workflow.
The upgrade integrates the company’s Micro-Neighborhood® Targeting (MNT) audiences, turning NLAB into a platform-agnostic, no-code audience tool for life sciences media planning. From one patient audience description, users can generate NPI lists and consumer segments in minutes and activate them across programmatic and major media channels. New DTC-focused features include decile-based, interactive views of audience quality and reach, plus instant media channel propensity and demographic insights for audience-specific media mix planning.
OptimizeRx (OPRX) announced that its management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference on September 10, 2026, in New York, NY.
The company describes itself as a healthcare technology provider whose AI-driven platform, including the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT), supports life science brands in engaging healthcare professionals and patients at key decision moments. OptimizeRx reports that it focuses on privacy-safe, patient-centric technology and partners with global pharmaceutical and life sciences companies. Meeting requests for the conference are directed through institutional contacts.
OptimizeRx (OPRX) appointed pharmaceutical commercialization and AI expert Troy Sarich as a company advisor to support its healthcare marketing technology strategy.
Sarich brings nearly 30 years of global healthcare, life sciences and pharma experience, including service as Chief Commercial Data Science Officer at Johnson & Johnson, where he advanced data-driven, AI-enabled commercial capabilities. At OptimizeRx, he will advise on the evolution of the company’s data and technology offerings to help life sciences brands, healthcare providers and patients engage more effectively at critical moments in care. The company highlights his background in data, analytics and artificial intelligence, as well as his work across cardiology, oncology, immunology and neuroscience.
OptimizeRx (Nasdaq: OPRX) announced a planned finance leadership transition effective January 1, 2027. The Board appointed Andy D’Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer, while current CFO & Strategy Officer Ed Stelmakh will remain in his role through December 31, 2026.
According to the company, Stelmakh will then serve as Strategic Advisor through 2027 to support continuity. The company credits him with expanding margins, improving cost of capital through debt refinancing, integrating the Medicx acquisition, divesting non-core assets, and building a high-performing, succession-ready finance organization. The company states that its financial and growth strategy remains unchanged.
OptimizeRx (Nasdaq: OPRX) reported Q2 2026 revenue of $20.5 million, down 30% from $29.2 million in Q2 2025. The company posted a GAAP net loss of $0.7 million ($0.04 per share) versus prior-year GAAP net income of $1.5 million, while non-GAAP net income was $3.1 million ($0.16 per diluted share). Adjusted EBITDA was $4.9 million, compared with $5.8 million a year earlier.
OptimizeRx reaffirmed its 2026 outlook for revenue of $95–$100 million and adjusted EBITDA of $21–$25 million. The company completed a $35 million bank refinancing (a $25 million term loan and $10 million undrawn revolver) and has repaid $8.3 million of principal since inception. Cash and equivalents were $24.1 million as of June 30, 2026. Rolling 12‑month net revenue retention declined to 90% from 121%.
OptimizeRx (Nasdaq: OPRX) will host a conference call on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026. The results will be released in a press announcement before the call.
According to OptimizeRx, investors can join via toll-free phone at 1-877-407-9716, international at 1-201-493-6779, or through a webcast at https://viavid.webcasts.com/starthere.jsp?ei=1770269&tp_key=7d483832d3. A replay will be available for 12 months in the investors section of the company’s website.
OptimizeRx (Nasdaq: OPRX) appointed veteran pharmaceutical marketing executive Sarah Bast as Chief Marketing Officer, effective July 23, 2026. Bast has more than 20 years of experience in point of care media strategy, analytics, and optimization across major healthcare marketing organizations.
She most recently served as Executive Vice President, Investment Marketplace at Publicis Health Media, where she led partnerships and solutions for major pharmaceutical brands and specialized in POC media, EHRs, and telehealth. At OptimizeRx, Bast will oversee marketing strategy, brand positioning, and go-to-market initiatives, with a focus on strengthening relationships with healthcare marketing agencies and life sciences teams and supporting product innovation and commercial growth.
OptimizeRx (Nasdaq: OPRX) launched CopayCue, a copay activation solution that uses real-time HCP prescribing intent to deliver brand savings offers directly within e-prescribing workflows.
Powered by data from 400+ EHR/e-prescribing platforms, it can engage 900K authenticated HCPs and has shown prescription lift of 4–5% over EHR banners and 11.5% in standalone programs.
OptimizeRx (Nasdaq: OPRX) launched its patent-pending Natural Language Audience Builder (NLAB), an AI tool embeddable in life sciences DSPs and agency media planning platforms.
NLAB uses real-world evidence and OptimizeRx’s EHR network to let pharma and agencies build, refine, and activate custom HCP audiences via natural-language prompts. Platform integration starts August 2026.